Welcome to our dedicated page for Axsome Therapeutics SEC filings (Ticker: AXSM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Axsome Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Axsome Therapeutics's regulatory disclosures and financial reporting.
Murdock Hunter R. reported acquisition or exercise transactions in this Form 4 filing.
Axsome Therapeutics, Inc. reported that its General Counsel, Hunter R. Murdock, received a grant of 7,224 Performance Stock Units (PSUs). Each PSU represents a contingent right to receive one share of Axsome common stock. The PSUs will vest only if specified sales and commercial launch milestones are achieved and if the executive continues in service through each vesting date. Following this award, Murdock holds 7,224 PSUs directly.
Axsome Therapeutics entered into an asset purchase agreement with Takeda to obtain exclusive global commercial, development, and manufacturing rights to balipodect (TAK-063), a novel, oral, selective PDE10A inhibitor. Axsome plans to develop balipodect for schizophrenia and Tourette syndrome and to start Phase 3 trial-enabling activities for schizophrenia in 2026.
Balipodect has completed a 164-patient proof-of-concept Phase 2 trial in schizophrenia and has shown a favorable safety and tolerability profile in clinical studies in over 360 individuals. Takeda received an upfront payment and may receive additional development, regulatory, and commercial milestone payments, plus royalties on potential global net sales.
The Vanguard Group filed an amendment to a Schedule 13G reporting its beneficial ownership in Axsome Therapeutics Inc. The filing states 0 shares beneficially owned, representing 0% of the class as reported in the amendment dated 03/13/2026.
The filing explains an internal realignment effective January 12, 2026 that led certain Vanguard subsidiaries and business divisions to report ownership separately; the statement clarifies those entities pursue the same investment strategies previously followed.
TABUTEAU HERRIOT reported acquisition or exercise transactions in this Form 4 filing.
Axsome Therapeutics, Inc. reported that Chief Executive Officer Herriot Tabuteau received a grant of 54,623 restricted stock units. Each RSU represents a contingent right to receive one share of Axsome common stock.
According to the award terms, 25% of the RSUs vest on the one-year anniversary of the grant date, with the remaining units vesting in three substantially equal annual installments so that all RSUs are fully vested on February 26, 2030. Vested shares will be delivered to Tabuteau upon the earlier of a qualifying change in control of Axsome, his separation of service (including certain terminations, death, or disability), or seven years from the grant date.
Pizzie Nick reported acquisition or exercise transactions in this Form 4 filing.
Axsome Therapeutics, Inc. reported that its Chief Financial Officer, Nick Pizzie, received a grant of 18,570 Restricted Stock Units (RSUs) on February 26, 2026. Each RSU represents a contingent right to receive one share of Axsome common stock.
According to the award terms, 25% of the RSUs vest on the one-year anniversary of the grant date, with the remaining units vesting in three substantially equal annual installments so that all RSUs are fully vested by February 26, 2030. Vested shares will be delivered upon the earlier of a qualifying change in control, the CFO’s separation of service under specified conditions, or seven years from the grant date.
Murdock Hunter R. reported acquisition or exercise transactions in this Form 4 filing.
Axsome Therapeutics reported that its General Counsel, Hunter R. Murdock, received a grant of 16,385 restricted stock units (RSUs) of company common stock. Each RSU represents a right to receive one share at a future date.
According to the award terms, 25% of the RSUs will vest on the one-year anniversary of the grant date. The remaining units will vest in three substantially equal annual installments, so that all RSUs are fully vested by February 26, 2030. Vested shares will be delivered to Murdock upon the earlier of a qualifying change in control, his separation from the company (including termination, death, or total and permanent disability), or seven years from the grant date.
Maizel Ari reported acquisition or exercise transactions in this Form 4 filing.
Axsome Therapeutics Chief Commercial Officer Ari Maizel received a grant of 16,385 restricted stock units (RSUs) of company common stock. Each RSU represents the right to receive one share in the future, subject to vesting and service conditions.
According to the award terms, 25% of the RSUs will vest on the one-year anniversary of the grant date, with the remaining RSUs vesting in three substantially equal annual installments so that the award is fully vested on February 26, 2030. Shares will be delivered to Maizel upon the earlier of a qualifying change in control, his separation of service under specified conditions, or seven years from the grant date.
Jacobson Mark L. reported acquisition or exercise transactions in this Form 4 filing.
Axsome Therapeutics awarded Chief Operating Officer Mark L. Jacobson 19,663 restricted stock units (RSUs), each representing a contingent right to receive one share of common stock. This is an equity-based compensation grant, not an open-market share purchase or sale.
25% of the RSUs will vest on the one-year anniversary of the grant date. The remaining units will vest in three substantially equal annual installments so that all RSUs are fully vested by February 26, 2030. Vested shares will be delivered upon the earlier of a qualifying change in control, Jacobson’s separation of service (including certain terminations, death, or total and permanent disability), or seven years from the grant date.
Axsome Therapeutics director Mark Coleman reported an open‑market sale of 25,000 shares of common stock. The sale occurred on February 26, 2026 at a weighted average price of $161.11 per share, as part of a pre‑approved Rule 10b5‑1 trading plan that has now been completed.
The sold shares were underlying stock from previously exercised options. After this transaction, Coleman holds 47,140 Axsome shares directly. He is also deemed to beneficially own 403,856 additional shares indirectly through an entity over which he has voting and dispositive power.